Wei Hou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wei Hou has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- An Qin
Department of Orthopaedics, Shanghai Key Laboratory of Orthopaedic Implant, Shanghai Ninth People' s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China
1 shared publication Hailong Ma
Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine
1 shared publicationHang Zhang
Shanghai Key Laboratory of Orthopedic Implants, Department of Orthopedic Surgery, Shanghai Ninth People's Hospital
1 shared publication- Hongtao Xu
Shanghai Institute for Advanced Immunochemical Studies & School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China
1 shared publication Jie Li
ShanghaiTech University
1 shared publication- Peixiang Ma
Shanghai Key Laboratory of Orthopedic Implants, Department of Orthopedics, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200025, China
1 shared publication
Latest Publications
- Open Access
- 11 September 2025
- Published by Springer Nature in Research Square
Discovery of hALPL Agonists for Osteogenesis from A Selenium-containing DNA-encoded Natural Product Library
Tissue-nonspecific alkaline phosphatase (hALPL) deficiency or dysfunction is a key driver of bone developmental abnormalities. However, no small-molecule agonists are available for the therapeutic target hALPL—particularly its pathogenic mutants. We bridge this gap by developing an antibody maturation-inspired chemical maturation strategy that integrates DNA-encoded library (DEL) selection with parallel synthesis for rapid functional chemical discovery. Using a selenium-containing DNA-encoded natural product library (Se-nDEL), comprising 25900 selenium-containing derivatives and affinity-based selection, we identified hALPL-binding candidates. The candidates were further functionally matured via selenium-nitrogen exchange (SeNEx) chemistry-enabled in situ nanomole-scale parallel synthesis. These efforts culminated in the identification of E7, the first small-molecule hALPL agonist, which directly binds to and activates hALPL, thereby promoting osteogenesis both in vitro and in vivo. Notably, E7 demonstrated the ability to restore the enzymatic activities of seven pathogenic mutations, further highlighting its therapeutic potential. Our work establishes a scalable platform for agonist development, combining DEL-driven hit discovery with parallel synthesis for functional optimization, with broad applicability to challenging targets in bone biology and beyond.
- 11 September 2025
- Published by Springer Nature in Research Square
Open AccessDiscovery of hALPL Agonists for Osteogenesis from A Selenium-containing DNA-encoded Natural Product Library
Tissue-nonspecific alkaline phosphatase (hALPL) deficiency or dysfunction is a key driver of bone developmental abnormalities. However, no small-molecule agonists are available for the therapeutic target hALPL—particularly its pathogenic mutants. We bridge this gap by developing an antibody maturation-inspired chemical maturation strategy that integrates DNA-encoded library (DEL) selection with parallel synthesis for rapid functional chemical discovery. Using a selenium-containing DNA-encoded natural product library (Se-nDEL), comprising 25900 selenium-containing derivatives and affinity-based selection, we identified hALPL-binding candidates. The candidates were further functionally matured via selenium-nitrogen exchange (SeNEx) chemistry-enabled in situ nanomole-scale parallel synthesis. These efforts culminated in the identification of E7, the first small-molecule hALPL agonist, which directly binds to and activates hALPL, thereby promoting osteogenesis both in vitro and in vivo. Notably, E7 demonstrated the ability to restore the enzymatic activities of seven pathogenic mutations, further highlighting its therapeutic potential. Our work establishes a scalable platform for agonist development, combining DEL-driven hit discovery with parallel synthesis for functional optimization, with broad applicability to challenging targets in bone biology and beyond.